Pure Global

Positive control material for in situ hybridization to determine the integrity of DNA - Vietnam Registration 240000668/PCBB-HCM

Access comprehensive regulatory information for Positive control material for in situ hybridization to determine the integrity of DNA in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TTBYT Loại B medical device is registered under number 240000668/PCBB-HCM and manufactured by Ventana Medical Systems, Inc.. The authorized representative in Vietnam is CÔNG TY TNHH ROCHE VIỆT NAM.

This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.

Free Database
Powered by Pure Global AI
300,000+ Devices
240000668/PCBB-HCM
Registration Details
Vietnam MOH Registration: 240000668/PCBB-HCM
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Device Details

Positive control material for in situ hybridization to determine the integrity of DNA
VN: Vật liệu kiểm soát dương tính xét nghiệm lai tại chỗ để xác định sự bảo toàn của DNA
Risk Class TTBYT Loại B

Registration Details

240000668/PCBB-HCM

000.00.19.H29-240318-0003

Alu Positive Control Probe

05278694001

Company Information

Ventana Medical Systems, Inc.

Technical Details

Alu Positive Control Probe is a mixture of fluorescently labeled oligonucleotide probes used in the laboratory as a positive control material (positive control sample) to determine the integrity of DNA in the process of sample collection and processing, in formalin-fixed paraffin-embedded tissue sections. This product must be interpreted by a pathologist with combined expertise in histology, relevant clinical information, and appropriate control material (positive control sample). This product is intended for in vitro diagnostic use (IVD).

Dates and Status

Apr 01, 2024